

**53** OBERDISSE, U\*, G. HÖVNER, W\* BURGER\* B. WEBER  
 Depts. Pediat. and Ophtalmol., FU Berlin  
 Development of retinopathy in diabetic (D)  
 children and adolescents.

120 D children, adolescents, and young adults (66 ♂ and 54 ♀), aged betw. 6.5 and 27.5 yrs, 90 of which had entered or completed puberty (>T II), were subjected to a thorough ophtalm. examination including fluorescein angiography (FA) and photographic documentation of the right fundus. D duration ranged between 1 and 20 yrs (groups 1: 1-4.9 y (n=57); 2: 5-9.9 (37); 3: 10-14.9 (19); 4: >15 (7)). Metabolic control was evaluated using outpatient visit measurements of glucosuria, post-prand. blood glucose, growth and weight increments, and episodes of severe metabolic derangements. Ophtalmoscopy and fundus photogr. revealed vascular changes in 10%, while FA documented microangiopathy (Stages I: 1-5 microaneurysms (MA); II: 6-10 MA; III: >11 MA; IV: proliferative retinopathy) in 30% of these pat. Its incidence increased with age (from 0% <10 to 50% >16 yrs), duration of D (4% in group 1, 38% in 2, 53% in 3, and 86% in 4, 3/4 of all changes representing stage I) and deterioration of control (13% foll. longterm "good"; 29% foll. "fair", and 38% foll. "poor" control). Adolesc. females tended to show more severe changes. In 3 young women aged 17, 20, and 21 yrs, proliferative retinopathy was found after 7, 8, and 11 yrs of D. One of these had maintained "good" control during 7 out of 8 yrs of D.

**54** H. STOLECKE and W. ANDLER\*  
 Dept. of Paediat. Endocrinology, Children's Hospital,  
 Univ. of Essen, FRG

The influence of human growth hormone (HGH) on the thyroxine (T<sub>4</sub>)-triiodothyronine (T<sub>3</sub>)-ratio in HGH deficient patients.

To study the HGH-dependency of the T<sub>4</sub>-T<sub>3</sub>-conversion rate 12 patients with proven HGH-deficiency were examined. 8 patients showed additionally an impaired TSH secretion compatible with secondary hypothyroidism. T<sub>4</sub>, T<sub>3</sub>, TSH and TBG were measured by specific radioimmunoassay a) under current substitution therapy, b) after its cessation for at least 4 weeks and c) after recommencement in two weeks intervals.

**Results:** Under current therapy all values were in the normal range. After cessation of therapy, T<sub>4</sub> decreased in all patients with hypothyroidism below 5, 0 mcg% while T<sub>3</sub> kept the level >80 ng% in 3 cases and was found below the lower limit in the other 5 patients. TSH levels remained unchanged in the normal or low basal range. In the 4 patients with isolated HGH deficiency T<sub>4</sub> and T<sub>3</sub> remained as to be expected in the normal range. 4-6 weeks after recommencement of the prior therapy there was in all cases including those with isolated HGH deficiency a HGH dependent increase of T<sub>4</sub> - T<sub>3</sub> - ratio due to a slight or moderate decrease of T<sub>4</sub> and an increase of T<sub>3</sub>.

**Conclusion:** In HGH deficient patients with or without additional anterior pituitary insufficiencies HGH substitution cause a significant enhancement in the conversion of T<sub>4</sub> to T<sub>3</sub>.

**55** J. SACK, Z. BAR-ON\*, J. SHEMESH\*, R. BECKER\*, Pediatric Endocrinology, Chaim Sheba Medical Center, Israel.

Serum T<sub>4</sub> T<sub>3</sub> TBG T<sub>3</sub> uptake concentrations in childhood and puberty.

Measurements of serum thyroxine (T<sub>4</sub>) thyroxine binding globulin (TBG) and triiodothyronine (T<sub>3</sub>) using RIA as well as T<sub>3</sub> uptake % (T<sub>3</sub> U) free thyroxine index (FT<sub>4</sub>I) and free T<sub>3</sub> index (FT<sub>3</sub>I) were conducted in 200 healthy Israeli children. Their age ranged from 1 to 17 years. 140 children from the age of 8 years were divided into five groups according to Tanner's puberty stages. There were no significant age related changes in TBG and T<sub>3</sub>U. Linear regression of serum conc. of T<sub>4</sub> T<sub>3</sub> and FT<sub>4</sub>I showed that each decreased significantly (P < 0.001) with age, while FT<sub>3</sub>I did not change significantly. The correlation with Tanner's staging showed a significant decrease in T<sub>4</sub> and TBG conc. after mid-puberty (between stages P<sub>2</sub> and P<sub>4</sub>). T<sub>3</sub> however, decreased only toward the last stage of puberty (between P<sub>4</sub> to P<sub>5</sub>). Our present data indicate that the decrease in T<sub>4</sub> and T<sub>3</sub> conc. are not only due to the decrease in TBG conc. before puberty, however, during puberty TBG might play a more significant role in the decrease of thyroid hormone concentrations.

**56** W.A. STÖGMANN\* (Intr. by W. Swoboda), M. BORKEN-STEIN\*, Pediatric Clinic, G. STÖFFLER\* and G. FUEGER\*, Clinic of Radiology, Graz, Austria.

Normal values for circulating thyroid hormones (T<sub>4</sub>, T<sub>3</sub>, reverse T<sub>3</sub>), T<sub>3</sub> uptake and Thyrotropin (before and after TRH) of Austrian children.

182 Austrian children (all using Austrian "Vollsalz" with 10mg KJ/kg salt), aged 2 months till 14 years, were investigated in a cross sectional study with the approval of their parents. Measurements of T<sub>4</sub>, T<sub>3</sub>, rT<sub>3</sub>, T<sub>3</sub>U and TSH (before and after TRH 5mcg/kg) were done by RIA. Free T<sub>4</sub>RIA- and free T<sub>3</sub>RIA-indices and the ratio rT<sub>3</sub>/T<sub>3</sub> were calculated. Results:

T<sub>4</sub> mcg/dl T<sub>3</sub> ng/dl rT<sub>3</sub> ng/ml TSH mcU/ml 0'  
 X ± SD 8.05 ± 2.01 108.8 ± 33.8 0.27 ± 0.09 2.25 ± 1.96  
 range 6.04-12.07 73.9-174.4 0.18-0.44 0.0-6.16  
 TSH mcU/ml 30' rT<sub>3</sub>/T<sub>3</sub> FT<sub>3</sub>I FT<sub>4</sub>I  
 X ± SD 14.33 ± 9.29 0.24 ± 0.02 3.14 ± 0.6 0.22 ± 0.05

Geometric mean serum concentrations of T<sub>4</sub>, T<sub>3</sub>, rT<sub>3</sub> and TSH (basal) were not age related different; T<sub>4</sub> showed a not significant negative slope with ageing. The geometric mean values of T<sub>3</sub>U were different between the age groups. The ratio rT<sub>3</sub>/T<sub>3</sub> remains constant. TRH induced TSH release is unchanged from 2 months till 14 years. Our results differ in part to those of the literature.

**57** B. Godó\*, H.K.A. Visser and H.J. Degenhart.  
 Dept. of Pediatrics, Medical Univ. Szeged,  
 Hungary. Dept. of Pediatrics, Erasmus Univ.  
 Rotterdam, The Netherlands.

Plasma 17-OH-progesterone at birth and during the early neonatal period in full term and preterm infants.

Assessment of plasma 17α-OH-progesterone (17-OHP) provides a valuable aid in the clinical diagnosis and management of congenital adrenal hyperplasia. However, for this to be useful it is necessary to know the normal values. In contrast to the large number of investigations in full term infants, insufficient data are available concerning 17-OHP levels in preterm infants. In full term and in preterm infants cord and periperal blood 17-OHP levels were determined, using a commercially available RIA-kit (Sorin). The results (in ng/ml ± S.E.M.) are summarized in the following table.

	Cord blood	Peripheral blood (1st week of life)
Full term	31 ± 1 (n = 45)	2.1 ± 0.2 (n = 51)
Preterm	17 ± 2 (n = 24)	4.1 ± 0.2 (n = 59)

The means found for two groups of infants differ significantly (p < 0.001). No differences were found in 17-OHP concentration between male and female infants.

**58** J. Homoki\*, W.M. Teller, Department of Pediatrics,  
 University of Ulm, Fed. Rep. Germany

Increased urinary excretion of 16α-hydroxy-pregnenolone in newborn infants with 21-hydroxylase deficiency.

Urinary excretion of total 16α-hydroxypregnenolone (16α-OH-P<sub>0</sub>), pregnanetriol (PT) and 11-oxopregnanetriol (11-O-PT) were determined by capillary gas chromatography in 18 healthy neonates and 3 newborn infants with congenital adrenal hyperplasia (CAH) during the first three weeks after birth. In the 4th week of life all CAH-infants demonstrated salt loosing crisis. Mean steroid excretion in µg/day (healthy infants vs. CAH (brackets)):

weeks	16α-OH-P <sub>0</sub>	PT	11-O-PT
1st	25	12	10
2nd	214 (1317)	49 (93)	141 (142)
3rd	480 (2955)	39 (61)	85 (968)

**Conclusion:**

The determination of urinary excretion of 16α-OH-P<sub>0</sub> is a valuable tool in the reliable detection of 21-hydroxylase deficiency during the first weeks of life when conventional tests may fail.

Supported by DFG SFB 87 Project C-3